Guardant Health (GH) Earnings Date & Reports

Key Takeaways

• Guardant Health reported third-quarter 2026 revenue of $361 million, up 36% year over year and above the consensus estimate of roughly $351 million.
• Adjusted (non-GAAP) net loss narrowed to $0.29 per share, better than the consensus estimate of about $0.31 per share.
• Oncology revenue grew 25% to $231.3 million, while Shield screening revenue surged 180% to $67.6 million on test volume that more than tripled.
• Full-year 2026 revenue guidance was raised to $1.36–$1.37 billion, but free cash flow burn guidance was also increased, disappointing investors.
• Shares fell by a double-digit percentage in after-hours trading, reflecting concerns about cash burn despite strong top-line growth.
• For more context on Guardant Health's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for deeper insight.
• You can also explore Trending AI Robots to discover AI-driven trading strategies across the market.

Earnings Context and Why It Matters

Guardant Health is a leading precision oncology company whose blood-based tests span cancer screening, therapy selection, and monitoring. Its third-quarter 2026 report carried outsized weight because it offered a read on two closely watched growth engines: the Shield blood test for colorectal cancer screening and the Guardant360 oncology franchise. After a record second quarter, investors were focused on whether Shield's commercial ramp could sustain momentum amid expanding payer coverage and on the pace of cash investment required to scale that business. The results landed against a volatile backdrop for blood-testing stocks, making the company's guidance updates and free cash flow trajectory as important as its headline revenue beat.

Reported Results

For the third quarter ended September 30, 2026, Guardant Health reported revenue of $361 million, a 36% increase from $265 million in the prior-year period and above the consensus estimate of roughly $351 million. Adjusted (non-GAAP) net loss was $0.29 per share, narrower than the consensus estimate of approximately $0.31 per share and an improvement from a $0.39 adjusted loss a year earlier. On a GAAP (generally accepted accounting principles) basis, net loss per share was $0.93.

Growth was broad-based. Oncology revenue rose 25% to $231.3 million, driven by a 58% increase in test volume to 117,000 tests. Screening revenue climbed 180% to $67.6 million, with Shield test volume more than tripling to 83,000 tests. Biopharma & Data revenue increased 8% to $59 million. The company raised its full-year 2026 revenue outlook to $1.36–$1.37 billion, up from $1.34–$1.36 billion, while also lifting its free cash flow burn guidance to $205–$220 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Guardant Health and the broader diagnostics sector, it offers a structured way to surface new opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Despite the top-and-bottom-line beat, Guardant Health shares tumbled roughly 12% to 14% in after-hours trading following the report. The stock had already declined about 9% during the regular session, pressured by weakness across the blood-testing sector. Investors appeared to focus on the raised free cash flow burn guidance, which signaled that scaling the Shield screening business will require more investment than previously expected. The negative reaction underscored a recurring theme for high-growth diagnostics names: strong revenue momentum alone may not be enough to satisfy investors when spending levels also move higher.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching several factors tied to Shield's commercial ramp and the broader oncology portfolio. Management indicated that payer coverage momentum continued in the quarter, with new policies expected to bring the Shield blood test to roughly 100 million covered lives, or more than 80% of the eligible U.S. screening population, entering 2027. The pace at which expanded coverage translates into sustained test volume and stable pricing will be a central focus.

Regulatory and reimbursement milestones also matter. Guardant Health received FDA (U.S. Food and Drug Administration) approval for Guardant360 CDx for longitudinal ESR1 testing in breast cancer and is pursuing ADLT (Advanced Diagnostic Laboratory Test) designation for Guardant360 Liquid CDx in the first half of 2027, which could support higher reimbursement. Progress on the Reveal minimal residual disease franchise and the planned launch of the higher-sensitivity Reveal Ultra test represent additional catalysts.

Finally, cost discipline will remain in focus. The raised cash burn outlook, combined with ongoing investment in screening infrastructure, means investors will monitor whether Shield's cost per test continues to decline and whether the company stays on track toward its long-term cash-flow breakeven target. These dynamics, rather than headline revenue growth alone, are likely to shape sentiment in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations